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Aims The relative benefits of computed tomography coronary angiography (CTCA)-guided management in women and
men with suspected angina due to coronary heart disease (CHD) are uncertain.
...................................................................................................................................................................................................
Methods
and results
In this post hoc analysis of an open-label parallel-group multicentre trial, we recruited 4146 patients referred for as-
sessment of suspected angina from 12 cardiology clinics across the UK. We randomly assigned (1:1) participants to
standard care alone or standard care plus CTCA. Fewer women had typical chest pain symptoms (n= 582, 32.0%)
when compared with men (n= 880, 37.9%; P< 0.001). Amongst the CTCA-guided group, more women had normal
coronary arteries [386 (49.6%) vs. 263 (26.2%)] and less obstructive CHD [105 (11.5%) vs. 347 (29.8%)]. A CTCA-
guided strategy resulted in more women than men being reclassified as not having CHD {19.2% vs. 13.1%; absolute
risk difference, 5.7 [95% confidence interval (CI): 2.7–8.7, P< 0.001]} or having angina due to CHD [15.0% vs. 9.0%;
absolute risk difference, 5.6 (2.3–8.9, P= 0.001)]. After a median of 4.8 years follow-up, CTCA-guided management
was associated with similar reductions in the risk of CHD death or non-fatal myocardial infarction in women [hazard
ratio (HR) 0.50, 95% CI 0.24–1.04], and men (HR 0.63, 95% CI 0.42–0.95; Pinteraction = 0.572).
...................................................................................................................................................................................................
Conclusion Following the addition of CTCA, women were more likely to be found to have normal coronary arteries than
men. This led to more women being reclassified as not having CHD, resulting in more downstream tests and treat-
ments being cancelled. There were similar prognostic benefits of CTCA for women and men.
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Introduction
In the management of suspected stable angina, women are less likely
than men to be referred for cardiac investigations or undergo
coronary revascularization.1 This is despite a higher prevalence of an-
gina2 and a 50% higher lifetime risk of dying from coronary heart dis-
ease (CHD).3 Differences in clinical presentation in women
* Corresponding author. Tel: þ44 141 330 1671/þ44 141 951 5000, Fax: þ44 141 330 6794, Email: colin.berry@glasgow.ac.uk
VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestrict-
ed reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
European Heart Journal (2019) 00, 1–9 CLINICAL RESEARCH
doi:10.1093/eurheartj/ehz903 Coronary artery disease
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz903/5688932 by U
niversity of East Anglia user on 08 January 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
contribute to under-recognition and less intensive treatment,4,5 and
research studies in CHD may represent women less.6
Patients with stable chest pain are evaluated using anatomical imag-
ing with computed tomography coronary angiography (CTCA) or
functional testing including stress electrocardiography, radionuclide
scintigraphy, echocardiography, or magnetic resonance imaging.7–11
In the Scottish Computed Tomography of the Heart (SCOT-
HEART) trial, we reported that among patients referred for the
evaluation of stable chest pain, CTCA clarified the diagnosis and
altered subsequent management.12 At 5 years, CTCA-guided man-
agement added to standard care reduced the rate of death from
CHD or non-fatal myocardial infarction (MI).13
We investigated whether treatment and outcomes following
CTCA-guided management differ between women and men. We
hypothesized that there are sex differences for the diagnosis of CHD,
patient management (including investigations and treatment), and
clinical outcomes, including CHD death and MI, at 5 years.
Methods
Study population
The SCOT-HEART study was a prospective clinical trial investigating the
role of CTCA in patients aged between 18 and 75 years, referred to a car-
diology clinic with suspected angina due to CHD. Patients with a prior
history of CHD were eligible to participate. The standard care clinical as-
sessment included exercise electrocardiography. The study design and
principal findings12,13 have been reported previously. The study popula-
tion was randomized 1:1 to standard care or standard care plus >_64-slice
CTCA using a web-based system. Patients gave written informed
consent.
Procedures
Cardiovascular risk was calculated with the ASSIGN score. ASSIGN has
been developed, calibrated and validated for use in the UK.14
Obstructive coronary artery disease was defined as a luminal stenosis
>70% in one or more major epicardial vessel, or >50% stenosis in the left
main stem.15
At 6 weeks, attending clinicians were asked to review patients’ diagno-
sis and management in view of all available information including the
CTCA report (standard care plus CTCA) or the ASSIGN score (stand-
ard care alone). The clinician documented changes in diagnosis, investiga-
tions (stress testing or invasive coronary angiography), or treatments
(preventive and antianginal treatments). Anginal symptoms were assessed
by a self-administered Seattle Angina Questionnaire16 with telephone
follow-up for non-responders after two mailings 2 weeks apart.
Outcomes
The primary outcome of the trial was the proportion of patients diagnosed
with angina secondary to CHD at 6 weeks. A false-positive or negative
baseline diagnosis was determined to have occurred when the treating clin-
ician changed the diagnosis at 6 weeks. Key secondary outcomes included
changes in treatment or investigations at 6 weeks; CTCA findings; and
changes from baseline in Seattle Angina Questionnaire after 6 weeks and
6 months.12 The principal clinical endpoints included the composite of
death due to CHD or non-fatal MI and coronary revascularization proce-
dures. These events were identified with data from the Information and
Statistics Division of the National Health Service (NHS) Scotland and,
when appropriate, confirmed by review of patient health records.13
Statistical analyses
We performed a post hoc analysis stratified by sex. The analyses were per-
formed according to the intention-to-treat principle. Missing data were
removed from the analyses, except for data on deaths, which were cen-
sored at the time the patient was lost from the trial.
The diagnoses of CHD and angina due to CHD were assessed for cer-
tainty (yes/no vs. unlikely/probable in the primary analysis) and frequency
(yes/probable vs. unlikely/no) of diagnoses.
Changes in diagnosis, planned investigations, and medical therapies
were analysed within mixed-effects logistic regression models to calculate
odds ratio with sex included as an interaction term. We obtained stand-
ard errors for absolute risk reduction for each sex assuming that the dif-
ference in risk between CTCA and control arm was approximately
normal. The standard error for difference in absolute risk reduction be-
tween men and women was estimated as the square root of the sum of
the standard errors squared for each sex. As some of the numbers were
small, we repeated this analysis using simulation (sampling from Beta dis-
tributions) obtaining very similar results. Results are reported as odds
ratios and absolute risk reductions with 95% confidence intervals (CIs).
Clinical endpoint events were analysed with Cox regression models, simi-
larly adjusted, and cumulative event curves were constructed.
All analyses were performed using R software, version 3.5.0 (R
Foundation for Statistical Computing). Anonymized data will be made
available on request.
Results
Characteristics of the study participants
Between 18 November 2010 and 24 September 2014, 4146 (42%) of
9849 patients who had been referred for assessment of suspected an-
gina at 12 cardiology centres across the UK were enrolled and ran-
domly assigned to standard care or standard care and CTCA.
Of 4146 randomized patients, 1821 (44%) were women (Table 1
and Figure 1). Demographics and comorbidities were evenly distrib-
uted between the randomized groups. Compared to men, women
had a lower frequency of prior CHD in the standard care [49 (5.4%)
vs. 137 (11.8%), P< 0.001] and CTCA-guided groups [49 (5.4%) vs.
137 (11.8%), P< 0.001]. Fewer women were classified as having ‘typ-
ical’ chest pain symptoms in the CTCA-guided group [women: 281
(30.9%) vs. men: 456 (39.2%); P< 0.001] although no difference was
demonstrated within the standard care group [women: 301 (33.1%)
vs. men: 424 (36.5%); P= 0.117]. Women were half as likely to be
referred for invasive angiography in both groups [standard care,
women 76 (8.4%) vs. men 184 (15.8%); CTCA, women 59 (6.5%) vs.
men 196 (16.9%)].
Findings on computed tomography
coronary angiography
Of 2073 participants [n= 911 (44%) women] randomized to CTCA-
guided management, 1778 participants underwent CTCA (Table 2).
Eighty-one percent of women had a low coronary calcium score
(<100 AU), vs. 53% of men (P< 0.001). On CTCA, the proportion of
women with normal coronary arteries was two-fold higher than in
men, whereas 105 (11.5%) of 911 women had obstructive CHD,
which was nearly three-fold lower than in men [n= 347 (29.9%) of
1162, P< 0.001]. The proportions of men with single-, two-, and
2 K. Mangion et al.
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Table 1 Characteristics of the participants prior to randomization according to sex
Standard care P-value
(women vs. men)
Standard care1 CTCA P-value
(women vs. men)
Women Men Women Men
Number 910 1163 911 1162
Demographics
Age (years) 57.0 (9.2) 56.9 (10.0) 0.794 57.5 (9.7) 56.8 (9.7) 0.121
Body mass index (kg/m2) 29.9 (6.5) 29.6 (5.6) 0.229 30.4 (6.8) 29.2 (4.8) <0.001
Atrial fibrillation 13 (1.4) 28 (2.4) 0.153 11 (1.2) 33 (2.8) 0.016
Cardiovascular risk factors
Cigarette smokera 458 (50.4) 632 (54.5) 0.067 452 (49.7) 643 (55.4) 0.011
Hypertension 303 (33.6) 380 (33.0) 0.795 304 (33.7) 408 (35.5) 0.428
Diabetes mellitus 83 (9.1) 138 (11.9) 0.053 77 (8.5) 146 (12.6) 0.003
Hypercholesterolaemia 502 (55.2) 679 (58.4) 0.154 513 (56.3) 716 (61.6) 0.017
Family history 432 (47.7) 397 (34.6) <0.001 427 (47.5) 460 (39.9) 0.001
History of coronary heart disease 49 (5.4) 137 (11.8) <0.001 49 (5.4) 137 (11.8) <0.001
Medications
Anti-platelet medication 401 (44.1) 583 (50.1) 0.021 399 (43.8) 610 (52.5) <0.001
Statin 341 (37.5) 543 (46.7) <0.001 338 (37.1) 564 (48.5) <0.001
Beta-blockade 180 (19.8) 304 (26.1) 0.003 198 (21.7) 306 (26.3) 0.029
ACE-inhibitor/ARB 130 (14.3) 214 (18.4) 0.040 118 (13.0) 223 (19.2) <0.001
Calcium channel blocker 84 (9.2) 110 (9.5) 0.919 80 (8.8) 103 (8.9) 0.527
Nitrates 241 (26.5) 349 (30.0) 0.193 219 (24.0) 351 (30.2) 0.004
Other antianginal therapy 31 (3.4) 44 (3.8) 0.736 29 (3.2) 49 (4.2) 0.267
Anginal symptomsb 0.118 <0.001
Typical 301 (33.1) 424 (36.5) 281 (30.9) 456 (39.2)
Atypical 231 (25.4) 255 (22.0) 254 (27.9) 248 (21.3)
Non-anginal 377 (41.5) 482 (41.5) 375 (41.2) 458 (39.4)
Electrocardiogram
Normal 783 (87.0) 952 (82.7) 0.009 789 (88.1) 968 (84.0) 0.010
Stress electrocardiogram <0.001 <0.001
Performed 746 (82.3) 1007 (87.0) 756 (83.3) 1008 (87.1)
Normal 477 (69.4) 612 (64.4) 491 (69.0) 616 (65.3)
Inconclusive 129 (18.8) 154 (16.2) 139 (19.5) 146 (15.5)
Abnormal‡ 81 (11.8) 185 (19.5) 82 (11.5) 182 (19.3)
Further investigations
Stress imaging
Radionuclide 129 (14.2) 84 (7.2) <0.001 115 (12.6) 61 (5.2) <0.001
Other 7 (0.8) 6 (0.5) 0.719 6 (0.7) 9 (0.8) 0.504
Invasive coronary angiography 76 (8.4) 184 (15.8) <0.001 59 (6.5) 196 (16.9) <0.001
Baseline diagnosis of angina due to CHD <0.001 <0.001
No 103 (11.3) 163 (14.0) 110 (12.1) 157 (13.5)
Unlikely 524 (57.6) 537 (46.3) 525 (57.7) 538 (46.3)
Probable 239 (26.3) 363 (31.3) 240 (26.4) 362 (31.2)
Yes 43 (4.7) 98 (8.4) 35 (3.8) 105 (9.0)
Baseline diagnosis of CHD <0.001 <0.001
No 49 (5.4) 83 (7.1) 58 (6.4) 80 (6.9)
Unlikely 487 (53.6) 495 (42.6) 475 (52.2) 477 (41.0)
Possible 314 (34.5) 420 (36.2) 328 (36.0) 444 (38.2)
Yes 59 (6.5) 163 (14.0) 49 (5.4) 161 (13.9)
Values are expressed as n (%) or mean ± standard deviation. Missing data (standard care alone, standard care þ CTCA): atrial fibrillation n= 4 (3, 1); prior coronary heart dis-
ease n= 4 (3, 1); smoking habit n= 7 (5, 2); hypertension n= 41 (20, 21); hypercholesterolaemia n= 4 (3, 1); family history n= 43 (21, 22); angina symptoms n= 4 (3, 1); concomi-
tant therapies n= 4 for all (3, 1 for all); resting electrocardiogram n= 46 (22, 24); exercise electrocardiogram n= 18 (10, 8); exercise electrocardiogram outcome n= 234 (121,
113); further investigations n= 6 (4, 2); stress imaging n= 4 (3, 1); coronary angiography n= 4 (3, 1); and baseline diagnosis n= 4 (3, 1).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CHD, coronary heart disease.
aCurrent/ex-smokers.
bNational Institute for Health and Care Excellence criteria.
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three-vessel obstructive CHD were two to five-fold higher than in
women (Table 2 and Take home figure).
Baseline and 6-week diagnoses of
coronary heart disease and angina
due to CHD
Overall, CTCA resulted in more frequent diagnostic changes in
women than men (absolute risk difference 5.68, 95% CI: 2.71–
8.65, P-interaction < 0.001). Because standard care-guided man-
agement also resulted in more frequent changes in the diagnosis
of CHD amongst women than men, the relative benefits of
CTCA were similar [relative risk 14.6, 95% CI 8.6–27.5 (women)
vs. 16.9, 95% CI 9.2–35.6 (men), Table 3]. However, there were
important differences in the direction of this change in diagnosis.
CTCA-guided management was more likely to identify a false-
positive baseline CHD diagnosis amongst women [103 of 377
(27.3%) (CTCA) vs. 9 of 373 (2.4%) (standard care), number
needed to scan 4.0, 95% CI 3.4–5.0] compared with men [41 of
605 (6.8%) (CTCA) vs. 5 of 583 (0.9%) (standard care), number
needed to scan 16.9, 95% CI 12.4–26.7] (Supplementary material
online, Table S2, Take home figure). Conversely, the proportion of
false-negative baseline diagnoses was similar for women [72 of
533 (13.5%) (CTCA) vs. 3 of 536 (0.5%) (standard care), number
Figure 1 Trial design
.................................................................................................
Table 2 Findings disclosed by computed tomography
coronary angiography in men and women
Women
(N5 911)
Men
(N5 1162)
P-value
Coronary calcium score N = 787 N = 1006 <0.001
Low (<100 AU) 638 (81.1) 529 (52.6)
Medium (100–400 AU) 94 (11.9) 210 (20.9)
High (>400 AU) 55 (7.0) 267 (26.5)
Computed tomography
coronary angiography
N = 774 N = 997 <0.001
Normal 384 (49.6) 263 (26.3)
Non-obstructive CHD
Mild (<50%) 172 (22.2) 200 (20.0)
Moderate (50–70%) 113 (14.6) 187 (18.8)
Obstructive CHD
One-vessel 60 (7.8) 147 (14.7)
Two-vessel 31 (4.0) 97 (9.7)
Three-vessel 14 (1.8) 103 (10.3)
Values are expressed as n (%).
AU, Agatston Units; CHD, coronary heart disease.
4 K. Mangion et al.
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Take home figure Women were more likely than men to have (A) atypical chest pain and normal coronary arteries leading to (B) greater false-
positive diagnoses of coronary heart disease and angina due to coronary heart disease. Overall, women had low rates of clinical events (coronary
heart disease death or non-fatal myocardial infarction) at 5 years but derived a similar prognostic benefit from computed tomography coronary angi-
ography as men. (C) Cumulative event curves for the principal long-term clinical endpoint in those assigned to standard care plus computed tomog-
raphy coronary angiography (blue) and standard care alone (red) amongst women (solid lines) and men (dashed lines).
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..needed to scan 7.7, 95% CI 6.3–10.0] compared with men [111
of 557 (19.9%) (CTCA) vs. 3 of 578 (0.5%) (standard care), num-
ber needed to scan 5.2, 95% CI 4.4–6.3].
Similarly, regarding the classification of angina due to CHD, CTCA
changed the diagnosis in 54 (7.8%) of 694 men and 45 (7.1%) of 634
women thought not to have CHD and excluded the diagnosis in 51
(10.9%) of 467 men and 92 (33.7%) of 273 women (Take home figure).
As before, CTCA changed the diagnosis of angina due to CHD more
frequently in women compared with men (absolute risk difference
5.66, 95% 2.72–8.65, P-interaction = 0.007).
Changes in investigations and treatment
at 6 weeks
There were no differences in invasive coronary angiography or cor-
onary revascularization rates between standard care and CTCA-
guided care. CTCA-guided management resulted in cancellation of
tests (myocardial perfusion imaging and stress echocardiography)
with an absolute risk difference of 4.45 (95% CI: 2.25–6.65);
P< 0.001) and changes in antianginal therapy [absolute risk difference:
4.5 (95% CI: 1.9–7.2), P< 0.001]. CTCA-guided management resulted
in similar rates of changes to preventative therapy (Table 4).
Angina
There were no sex differences in physical limitation, angina stability,
frequency, satisfaction with treatment, and quality of life, as assessed
using the Seattle Angina Questionnaire, at 6 weeks and 6 months,
when compared with baseline observations (Table 1).
Clinical endpoints
After a median of 4.8-year follow-up, women had a lower composite
endpoint rate of death due to CHD or MI or death due to CHD, MI,
or stroke than men (Take home figure). Crude differences in health
outcomes and adjusted hazard ratios were observed between
women and men for CTCA-guided management vs. standard care
(Table 5).
Discussion
We have undertaken an analysis by sex of the main findings in the
SCOT-HEART trial. Compared with men, women had differences in
the typicality of their anginal symptoms, a higher likelihood of having
normal coronary arteries, and more frequent diagnostic and thera-
peutic changes with CTCA-guided management. In particular, CTCA
modified apparent over-diagnosis and treatment of women who had
been incorrectly diagnosed with CHD and angina due to CHD. Both
women and men appear to benefit equally from the addition of
CTCA to standard care with no evidence of an interaction between
sex and health outcomes identified.
In line with prior reports,17–19 women reported less typical anginal
symptoms making clinical assessment more challenging. This diagnos-
tic uncertainty, and lower prevalence of obstructive CHD, led to an
over-diagnosis of CHD and angina. Exercise electrocardiography
testing has limited sensitivity and specificity for the presence of cor-
onary artery disease, especially in women17 which may have contrib-
uted to misdiagnosis. Indeed, women were more likely to have
downstream non-invasive stress testing cancelled, and antianginal
Table 3 Change in diagnosis of coronary heart disease and angina
Change in diagnosis of CHD
Standard care, N (%) No change Change
Female 898 12
Male 1154 9
CTCA, N (%)
Female 736 175
Male 1010 152
Female Male Interaction
Odds ratio 17.8 (10.3–34.0) 19.3 (10.4–41.0) 1.1 (P = 0.860)
Absolute risk change 17.9% 12.3% P < 0.001
Difference in absolute risk 5.7 (2.7–8.7)
Change in diagnosis of angina due to CHD
Standard care, N (%) No change Change
Female 900 10
Male 1154 9
CTCA, N (%)
Female 774 137
Male 1057 105
Female Male Interaction
Odds ratio 15.9 (8.8–32.6) 12.7 (6.8–27.2) 0.8 (P = 0.642)
Absolute risk change 13.9% 8.3% P < 0.001
Difference in absolute risk 5.6 (2.2–8.8)
6 K. Mangion et al.
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..therapies reduced following reclassification by CTCA. On the other
hand, ischaemia and no obstructive coronary artery disease
(INOCA) caused by small vessel disease more commonly affects
women.20 We suggest that CTCA-guided diagnosis and management
is helpful in women for the diagnosis of angina due to CHD, but less
so for INOCA. These findings extend the sex subanalysis of the
CRESCENT (Calcium Imaging and Selective CT Angiography in
Comparison to Functional Testing for Suspected Coronary Artery
Disease) trial.21
When compared with exercise electrocardiography testing,
CTCA-guided therapy impacted on false-positive classifications with-
out affecting false-negative classifications in women. This is in contrast
to data published from the PROspective Multicentre Imaging Study
for Evaluation of chest pain (PROMISE) trial, where statin therapy
was lower in women than in men and women were less likely to be
referred for coronary angiography19. In PROMISE, 88% of
participants had chest pain (72%) or an anginal equivalent (16%),
whilst 10% had typical angina compared with SCOT-HEART where
100% had chest pain, 35% had typical angina and 9% had known
CHD. The standard of care was exercise electrocardiography and
the results of a trial involving different functional tests as standard of
care might be different.
In our study, patients were recruited from cardiology clinics rather
than general outpatient clinics. In SCOT-HEART, clinicians were free
to request other non-invasive stress imaging at their discretion and
indeed 10% of additional testing was requested, mostly radionuclide
scintigraphy. In contrast, in the functional testing arm of PROMISE,
radionuclide scintigraphy predominated (67%) with stress echocardi-
ography and electrocardiography accounting for the remainder. We
found that normal coronary arteries were two-fold more common in
women whereas obstructive CHD was three-fold more common in
men, similar to Pagidipati et al.19 This has important therapeutic
Table 4 Changes in investigations and treatments at 6 weeks
Preventative medications—change
Standard care, N (%) No change Change
Female 872 38
Male 1111 52
CTCA, N (%)
Female 749 162
Male 955 207
Female Male Interaction
Odds ratio 5.0 (3.5–7.3) 4.6 (3.4–6.4) P = 0.779
Absolute risk change 13.6% 13.3%
Difference in absolute risk reduction 0.3 (-3.5 to 4.0) P = 0.890
Antianginal medications—change
Standard care, N (%) No change Change
Female 902 8
Male 1155 8
CTCA, N (%)
Female 802 109
Male 1078 84
Female Male Interaction
Odds ratio 15.3 (7.9–34.4) 11.2 (5.8–25.3) P = 0.556
Absolute risk change 11.1% 6.5%
Difference in absolute risk reduction 4.5 (1.9–7.2) P < 0.001
Stress imaging investigations—change
Standard care, N (%) No change Change
Female 906 4
Male 1161 2
CTCA, N (%)
Female 832 79
Male 1116 46
Female Male Interaction
Odds ratio 21.5 (8.9–70.7) 23.9 (7.4–146.8) P = 0.904
Relative risk 19.7 (7.3–53.6) 23.9 (5.8–98.8)
Absolute risk change 8.2% 3.8%
Difference in absolute risk reduction 4.5 (2.3–6.7) P < 0.001
CTCA, computed tomography coronary angiography.
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implications for coronary revascularization rates and use of medical
therapy across genders.10 Symptoms and quality of life improve when
CTCA-guided management discloses normal coronary arteries22 and
this favourable outcome associates with female sex. Typical anginal
symptoms and obstructive CHD were less common in women,
reflecting aetiological differences, and manifest by lower rates of cor-
onary revascularization.17,18 These findings extend those of
PROMISE.23
Women are more likely to experience angina due to small vessel
disease,20 whereas obstructive CHD is more common in men. The
CorMicA trial recently provided evidence that in patients with angina
and no obstructive CHD, stratified medicine including adjunctive
tests of small vessel function leads to improvements in angina and
quality of life.20 The prevalence and clinical significance of small vessel
disease in patients with chest pain and normal coronary arteries or
non-obstructive CHD is being prospectively assessed in in the
Coronary Microvascular Function and CT Coronary Angiography
(CorCTCA) trial.24
There are sex differences in prognosis following a diagnosis of sta-
ble angina, which is notably worse in younger women than in men.17
These differences may be explained by under-use of relevant tests
and treatments.17 In our study, women had lower crude rates of ad-
verse cardiovascular events when compared with men, and a lower
rate of MI in both treatment arms. The magnitude and direction of
the benefits of CTCA on fatal and non-fatal MI were similar between
the sexes. There were no differences in the longer-term in coronary
angiography and revascularization rates between groups for both
women and men. There was a small numerically higher rate of non-
cardiac death and stroke events in women in the CT group vs. the
standard care group. The number of events was very low and difficult
to interpret.
The interaction tests for sex, treatment group allocation, and
health outcomes were not statistically significant (i.e. the null hypoth-
esis was not rejected). Thus, the benefits of CTCA-guided manage-
ment on health outcomes appear to be similar in women and men.
This finding contrasts with the PROMISE25 where women appeared
to gain more prognostic benefit than men from a CTCA-guided strat-
egy. A gender-specific post hoc analysis from DISCHARGE
(Diagnostic Imaging Strategies for Patients With Stable Chest Pain
and Intermediate Risk of Coronary Artery Disease, ClinicalTrials.gov
identifier: NCT02400229)26 would extend whether women benefit
from CTCA-guided strategy vs. invasive coronary angiography in the
investigation of CHD.
Limitations
There are a number of limitations associated with this study. First,
this was a post hoc analysis of an open-label trial and gender was not
randomized. Second, this study was not designed or powered for this
secondary analysis, and our findings are exploratory. Third, the small
numbers of changes in the standard care arm resulted in a large vari-
ability in the relative changes that it was not possible to draw any firm
conclusions from the logistic regression analyses. However, absolute
differences allow for different proportions of changes in the diagnosis
and establishes the gender differences we report. Finally, information
on microvascular dysfunction as an alternative cause of angina was
not available. Further studies are on-going.24
Conclusions
Women are less likely to have typical symptoms or obstructive CHD
but are more likely to be over-diagnosed. CTCA is useful in reducing
................................................................................................................................
................................................................. ............................................................
....................................................................................................................................................................................................................
Table 5 Clinical outcomes by sex and treatment group after a median of 4.8 years
Standard care vs. CTCA Interaction
P-valuea
Women Men
N (CTCA) N (standard
care)
HR (95% CI) N
(CTCA)
N (standard
care)
HR (95% CI)
CHD death or myocardial infarction 11 (1.2) 22 (2.4) 0.50 (0.24–1.04) 37 (3.2) 59 (5.1) 0.63 (0.42–0.95) 0.572
CHD death myocardial infarction or stroke 19 (2.1) 26 (2.9) 0.72 (0.40–1.30) 44 (3.8) 71 (6.1) 0.63 (0.43–0.91) 0.686
Cardiovascular events
Myocardial infarction 11 (1.2) 21 (2.3) 0.53 (0.25–1.10) 33 (2.8) 52 (4.5) 0.64 (0.41–0.99) 0.638
Stroke 8 (0.9) 5 (0.5) 1.57 (0.50–4.89) 7 (0.6) 15 (1.3) 0.47 (0.19–1.15) 0.099
Death
CHD 0 (0.0) 1 (0.1) — 4 (0.3) 8 (0.7) 0.51 (0.15–1.71) —
Cardiovascular 1 (0.1) 1 (0.1) 1.42 (0.08–24.38) 4 (0.3) 11 (0.9) 0.38 (0.12–1.20) 0.532
Non-cardiovascular 12 (1.3) 8 (0.9) 1.45 (0.59–3.56) 26 (2.2) 23 (2.0) 1.17 (0.67–2.06) 0.701
All-cause 13 (1.4) 9 (1.0) 1.42 (0.60–3.33) 30 (2.6) 34 (2.9) 0.92 (0.56–1.50) 0.403
Procedures
Coronary angiography 144 (15.8) 159 (17.5) 0.86 (0.69–1.09) 347 (29.9) 343 (29.5) 1.06 (0.91–1.22) 0.171
Coronary revascularization 53 (5.8) 45 (4.9) 1.15 (0.77–1.72) 226 (19.4) 222 (19.1) 1.05 (0.87–1.27) 0.652
Hazard ratios (HRs) were determined with Cox regression models adjusted for centre and minimization variables (age, body mass index, diabetes mellitus, prior coronary heart
disease, and atrial fibrillation).
aP-value for the interaction between sex and allocated treatment.
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..over-diagnosis and medication in women and identifies unrecognized
CHD equally in both sexes with similar prognostic benefits. More re-
search is needed to determine the causes of, and treatments for, an-
gina in women and men with angiographically normal coronary
arteries.
Supplementary material
Supplementary material is available at European Heart Journal online.
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